Clinical trial NCT00994422: Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects
Official title: A Double-Blind Randomized Study to Compare the Safety, Local Tolerability and Efficacy of a 0.5% Ivermectin Cream Compared to a Topical Vehicle Control in Subjects With Pediculus Humanus Capitis Infestation
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Head Lice
Keywords: PEDICULUS HUMANUS CAPITIS
Head Lice
Lead sponsor: Topaz Pharmaceuticals Inc
Sponsor class: INDUSTRY
First posted: 2009-10-14
Enrollment: 264
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to compare the safety and efficacy of a 0.5% ivermectin cream to a placebo in subjects infested with head lice when used in an "at home" environment.


Eligibility criteria: Inclusion Criteria:

* Subject must have an active head lice infestation defined as: At least 1 live louse (adult and/or nymph) present on the scalp and/or hair, as determined by a trained evaluator (with the exception of the male head of household who may self-assess as being lice free).
* Subject is male or female.
* Subject weighs at least 15kg (33 lbs).
* Subject is in good general health based on medical history.
* Each subject must have an appropriately signed Informed Consent agreement. A caregiver must sign an Informed Consent agreement for children not old enough to do so. Children of a specified age will be administered a child's assent form.
* The caregiver of a subject must be willing to allow all household members to be screened for head lice. If other household members are found to have an active head lice infestation, according to the criteria a (above), they must be willing and able to participate in the study. No more than one working male per family may be excluded from evaluation if he is self-assessed as being lice free and cannot come in due to his work schedule. If this individual may have lice, he must come to the test facility; otherwise the entire household will be excluded from study participation.
* Subject and/or their caregiver must be physically able and willing to apply the test article.
* Subject agrees not to use any other form of lice treatments (commercial, community-anecdotal, or mechanical/manual) while they are participating in the study.
* Following application and rinsing of Study Treatment, subject agrees not to shampoo, wash, or rinse their hair or scalp until the 24-hour post-treatment evaluation has been completed.
* Subject agrees that they will not cut or chemically treat their hair while they are participating in the study.
* Subject agrees to follow all study instructions.
* Female subjects of childbearing potential (including a female caregiver even if she is not being treated) must be willing to have a urine pregnancy test.
* In the event of a subject judged to be incapable of self-treating, the household must have a caregiver willing to apply the treatment at home.

Exclusion Criteria:

* History of irritation or sensitivity to ivermectin or the cream components, pediculicides or hair care products.
* Presentation at the treatment site with visible skin/scalp condition(s) that are not attributable to head lice infestation, such as an erythema score that is \>2, blisters, vesicles which, in the opinion of the investigative personnel or sponsor, will interfere with safety and/or efficacy evaluations.
* Presentation at the treatment site with eczema or atopic dermatitis on the skin/scalp.
* Treatment with a marketed pediculicide (Over the counter \[OTC\] or Prescription) in the last 7 days.
* Any condition or illness that, in the opinion of the investigator, may compromise the objective of the protocol.
* Is receiving any other treatment which, in the opinion of the investigator or study monitor, may interfere with the study results.
* Females (including caregivers who come in contact with the investigational product) who are pregnant, nursing or planning a pregnancy. (NOTE: female caregivers and all enrolled females of childbearing potential must have a negative urine pregnancy test prior to treatment). If a household has a pregnant female who has an active case of lice, the entire household is excluded from participation. If this pregnant household member does not have an active infestation, this individual must NOT be the caregiver (one who provides treatment to other household members).
* Is of child-bearing potential and unwilling to use an adequate method of contraception for the duration of the study. Adequate methods of contraception include: abstinence, vasectomized partner, oral birth control pills, birth control injections or patches, Intra Uterine Devices, condoms with a spermicidal jelly or a diaphragm with spermicidal jelly, surgical sterilization.
* Participation in a previous investigational drug study within the past 30 days.
* Does not understand the requirements for study participation and/or may likely exhibit poor compliance, in the opinion of the investigator.
* Does not have a known household affiliation with their household members (i.e., do not stay in one household consistently, sleeping at one place several nights and then at another place or location). Household is defined as living in a shared area or space (for example the same house or apartment unit).

Primary outcomes:
measure: Percentage of Participants With Treatment Success Following Treatment With Either Ivermectin or Placebo (Vehicle Control)
timeFrame: Days 2 up to Day 15 post-treatment
measure: Number of Participants Reporting Adverse Events Post-Treatment With Either Ivermectin or Placebo (Vehicle Control)
timeFrame: Day 1 up to Day 28 post-application
measure: Summary of the Reported Skin/Scalp Irritations Before and Post-treatment With Either Ivermectin or Placebo (Vehicle Control)
timeFrame: Day 1 up to Day 15 post-application
Secondary outcomes:
Other outcomes:
Locations:
city: Yuma
country: United States
facility: Cactus Kids Pediatrics
state: Arizona
city: Los Angeles
country: United States
facility: Impact Clinical Trials
state: California
city: Delray Beach
country: United States
facility: Lice Cleanique, LLC
state: Florida
city: St Petersburg
country: United States
facility: Hill-Top Research Corp
state: Florida
city: West Palm Beach
country: United States
facility: LSRN
state: Florida
city: Fridley
country: United States
facility: Minnesota Clinical Study Center
state: Minnesota
city: Albuquerque
country: United States
facility: Lovelace Scientific Resources, Inc.
state: New Mexico
city: Clyde
country: United States
facility: Haywood Pediatric Adolescent Medicine Group, PA
state: North Carolina
city: Miamiville
country: United States
facility: Hill Top Research Corp.
state: Ohio
city: Nashville
country: United States
facility: LSRN
state: Tennessee
city: Houston
country: United States
facility: Northeast Houston Pediatric Clinic
state: Texas
city: Norfolk
country: United States
facility: Virgina Clinical Research, Inc.
state: Virginia
Study officials:
affiliation: Sanofi Topaz
name: Medical Director
role: STUDY_DIRECTOR
References: